Evidence map›Paper›PMID 36131846›Full record

ArticleOpen forum infectious diseases2022

Reduction in Risk of Death Among Patients Admitted With COVID-19 Between the First and Second Epidemic Waves in New York City.

Anthony Bowen, Jason Zucker, Yanhan Shen, Simian Huang, Qiheng Yan, Medini K Annavajhala, Anne-Catrin Uhlemann, Louise Kuhn, Magdalena Sobieszczyk, Delivette Castor

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Anthony BowenDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, USA.ORCID https://orcid.org/0000-0003-1064-8372
Jason ZuckerDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, USA.ORCID https://orcid.org/0000-0001-6987-6412
Yanhan ShenGertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, USA.
Simian HuangDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, USA.
Qiheng YanGertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, USA.
Medini K AnnavajhalaDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, USA.
Anne-Catrin UhlemannDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, USA.
Louise KuhnGertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, USA.
Magdalena SobieszczykDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, USA.
Delivette CastorDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, USA.

Funding

Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
Columbia Collaborative HIV/AIDS Clinical Trials UnitU01AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HAMMER, SCOTT M · 2007 to 2011
$15.4M
Columbia Integrated Training Program in Infectious Diseases ResearchT32AI100852 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK, Anne-Catrin Uhlemann · 2013 to 2026
$2.2M
Harnessing Bioinformatics for HIV Prevention: Understanding Persistence in Comprehensive HIV Prevention ServicesK23AI150378 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ZUCKER, JASON · 2020 to 2024
$960k
NIAID NIH HHS K23 AI150378NIAID NIH HHS T32 AI100852NIAID NIH HHS U01 AI069470NIAID NIH HHS UM1 AI069470
6 · The paper itself

Abstract

Background: Many regions have experienced successive epidemic waves of coronavirus disease 2019 (COVID-19) since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with heterogeneous differences in mortality. Elucidating factors differentially associated with mortality between epidemic waves may inform clinical and public health strategies. Methods: We examined clinical and demographic data among patients admitted with COVID-19 during the first (March-August 2020) and second (August 2020-March 2021) epidemic waves at an academic medical center in New York City. Results: Hospitalized patients (n = 4631) had lower overall and 30-day in-hospital mortality, defined as death or discharge to hospice, during the second wave (14% and 11%) than the first (22% and 21%). The wave 2 in-hospital mortality decrease persisted after adjusting for several potential confounders. Adjusting for the volume of COVID-19 admissions, a measure of health system strain, accounted for the mortality difference between waves. Several demographic and clinical patient factors were associated with an increased risk of mortality independent of wave: SARS-CoV-2 cycle threshold, do-not-intubate status, oxygen requirement, and intensive care unit admission. Conclusions: This work suggests that the increased in-hospital mortality rates observed during the first epidemic wave were partly due to strain on hospital resources. Preparations for future epidemics should prioritize evidence-based patient risks, treatment paradigms, and approaches to augment hospital capacity.

Indexed as

COVID-19Cox regressionepidemicsmortality

Identifiers

PMID36131846
PMCPMC9452151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.